Comparing OFS Capital (NASDAQ:OFS) & Advanced Medical Isotope (OTCMKTS:RDGL)

OFS Capital (NASDAQ:OFS) and Advanced Medical Isotope (OTCMKTS:RDGL) are both finance companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for OFS Capital and Advanced Medical Isotope, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OFS Capital	1	1	0	0	1.50
Advanced Medical Isotope	0	0	0	0	0.00

OFS Capital presently has a consensus price target of $7.00, suggesting a potential upside of 39.72%. Given OFS Capital’s stronger consensus rating and higher possible upside, equities analysts plainly believe OFS Capital is more favorable than Advanced Medical Isotope.

Profitability

This table compares OFS Capital and Advanced Medical Isotope’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OFS Capital	7.52%	8.95%	3.41%
Advanced Medical Isotope	-6,144.90%	N/A	-113.56%

Earnings & Valuation

This table compares OFS Capital and Advanced Medical Isotope”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OFS Capital	$47.96 million	N/A	$28.44 million	$0.24	20.88
Advanced Medical Isotope	$30,000.00	1,046.11	-$2.91 million	N/A	N/A

OFS Capital has higher revenue and earnings than Advanced Medical Isotope.

Institutional and Insider Ownership

10.8% of OFS Capital shares are owned by institutional investors. 0.5% of OFS Capital shares are owned by insiders. Comparatively, 18.5% of Advanced Medical Isotope shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

OFS Capital has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Advanced Medical Isotope has a beta of -0.5, meaning that its stock price is 150% less volatile than the S&P 500.

Summary

OFS Capital beats Advanced Medical Isotope on 9 of the 10 factors compared between the two stocks.

About OFS Capital

OFS Capital Corporation is a business development company specializing in direct and fund investments as well as add-on acquisitions. It provides flexible capital solutions primarily through debt capital and to a lesser extent, minority equity investments serving the needs of U.S.-based middle-market companies across a broad array of industries. It does not invest in operational turnarounds or start-up businesses. For direct, it specializes in debt and structured equity investments, recapitalizations and refinancing, management and leveraged buyouts, acquisition financings, ownership transition, shareholder liquidity events, growth capital, independent sponsor transactions, ESOPs, and minority investments in the lower middle market companies. It invests in the aerospace and defense, business services, consumer products and services, construction & building, durable goods, capital equipment, automotive, food and beverage, healthcare & pharmaceutical, specialty chemicals, transportation cargo and logistics, value added distribution, franchising, and industrial and niche manufacturing sectors. The firm invests in companies based in United States. It seeks to invest between $3 million and $35 million, revenues between $15 million and $300 million, annual EBITDA between $5 million and $50 million, and Enterprise value between $10 million and $500 million. The firm seeks to invest in companies with debt investment values between $5 million and $25 million. The fund uses senior secured, unitranche loans, first-lien, second lien, subordinated/ mezzanine loans, warrants, and preferred equity securities and common equity securities. It prefers to take a minority as well as majority stake in the investments made. It also co-invests with its partners for additional capital.

About Advanced Medical Isotope

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.